Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Classement en actions #39175
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Prix de l'action
$0.378
Dernière synchronisation: 2024-05-24
Capitalisation boursière
$618.41K
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange NeuBase Therapeutics, Inc. (NBSE)

Catégorie

Historique du rendement du dividende pour NeuBase Therapeutics, Inc. (NBSE)
Le rendement du dividende (TTM) de NeuBase Therapeutics, Inc. (symbole boursier : NBSE) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de NeuBase Therapeutics, Inc. (NBSE) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
0.65%
BE